Navigation Links
Benaroya Research Institute evaluates immunology approach to blocking breast cancer
Date:4/18/2014

(Seattle, WA April 18, 2014) Benaroya Research Institute at Virginia Mason (BRI) recently received a grant to research how blocking a particular molecule in metastatic breast cancer reduces both the growth of primary tumors and the number of lung metastases. BRI scientists have found in models of the disease that blocking this protein can shrink tumors by 60 - 80 percent and can keep the tumor from metastasizing or spreading to the lung. The $1.8 million five-year grant comes from the National Cancer Institute of the National Institutes of Health.

"We are excited to pursue this area of cancer research that links tumor growth to the type of immune system molecules that my laboratory has focused on for many years," said the Principal Investigator of the grant, Steven F. Ziegler, PhD, Director of the Immunology Program at BRI. "We are looking at ways to block this protein in model systems that could be translated to humans. The goal of this work is to help develop a therapy to reduce primary breast cancer tumors, as well as the spread of this cancer to other areas. We also plan to study this in pancreatic and lung cancer as well because this protein plays a role in these diseases."

In a study of the protein, Thymic Stromal Lymphopoietin (TSLP), in allergic responses Dr. Ziegler and his team used lung cancer as a "negative control group" and surprisingly found very high levels of the protein in people with lung tumors. In 2005, Dr. Ziegler and his colleagues discovered that TSLP was instrumental in initiating the inflammatory cascade that leads to the development of asthma and other allergic diseases. Since then, the researchers also found TSLP to be critical in other immune system diseases. Dr. Ziegler has studied TSLP since l993 and has developed many tools and strategies for studying the protein.

BRI researchers will test several ways to block TSLP to evaluate potential for treatments to help eliminate the cancer. "We will assess the utility of measuring TSLP to inform prognosis and how this might indicate whether more specific treatment plans may be necessary in some cases," said Dr. Ziegler. His team also will be studying the protein versican that has been shown to turn on TSLP in tumor metastasis. Thomas Wight, PhD, BRI Director of the Matrix Biology Program, and a leading researcher of versican, will be a collaborator on the grant along with Scott Adams, PhD, Professor of Oncology, Department of Immunology at Roswell Park Cancer Institute. Emma Kuan, PhD, a postdoctoral fellow in Dr. Ziegler's laboratory, is a major contributor and researcher on the grant.


'/>"/>

Contact: Kay Branz
kbranz@benaroyaresearch.org
206-342-6903
Immune Tolerance Network
Source:Eurekalert

Related medicine news :

1. Benaroya Research Institute announces $4.4 million grant for type 1 diabetes
2. Benaroya Research Institute receives 7-year award to lead Immune Tolerance Network
3. UCLA Brain Injury Research Center gets NCAA funding for research on sports concussions
4. NIH awards $20 million over 5 years to train next generation of global health researchers
5. Researchers develop a new cell and animal model of inflammatory breast cancer
6. Researchers uncover a viable way for colorectal cancer patients to overcome drug resistance
7. Sexually abused boys at risk for more unsafe sex: UBC research
8. Researchers Find Gene Mutations That May Be a Key to Autism
9. LSUHSC research finds HPV-related head & neck cancers rising, highest in middle-aged white men
10. Researchers find evidence of banned antibiotics in poultry products
11. Presidential keynote address and new research highlights from the American Society of Pediatric Otolaryngology meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2017)... ... May 24, 2017 , ... ... Solutions is vehemently opposed to Donald Trump’s budget, “A New Foundation for American ... inspires fear, demonizes the poor, marginalizes underserved populations, undermines productivity, and destroys the ...
(Date:5/24/2017)... ... ... Medic CE , a Career Step company, is sponsoring a live, 1-hour ... Journal of Emergency Medical Services (JEMS). The free webinar, to be held on Wednesday, ... Duckworth, LP, a career fire captain as well as founder and director of the ...
(Date:5/24/2017)... ... 24, 2017 , ... Rob Lowe is a sought after actor, and also ... brings the public important topics from all aspects of life, and a new segment ... surrounding feet and ankles. , Podiatry is essential to people’s overall well-being, and if ...
(Date:5/24/2017)... MN (PRWEB) , ... May 24, 2017 , ... ... of polyvinylidene fluoride (PVDF) based sleep diagnostics sensors, announced today it had completed ... now consists of a mix of domestic and rest of world (ROW) authorized ...
(Date:5/23/2017)... ... May 23, 2017 , ... PM360, the premier information ... announced the winners of its 3rd Annual ELITE Awards. The ELITE (Exceptional • ... the healthcare industry today. , Out of more than 500 submissions, 100 winners ...
Breaking Medicine News(10 mins):
(Date:5/3/2017)... Md. , May 3, 2017  Kalorama ... growth of nine percent next year and this ... organ and hematopoietic stem cell (HSCT) or bone ... donor. Molecular testing technologies are well-suited for this task. ... market research publisher Kalorama Information. The various PCR-based ...
(Date:5/3/2017)... Pa. , May 3, 2017  West ... in innovative solutions for injectable drug administration, announced ... Scientific Affairs and Technical Services, and Diane ... workshops and offering presentations focused on West,s expertise ... injectable products, as well as providing commentary on ...
(Date:5/2/2017)... , May 2, 2017  George Clinical, a ... region, and Vector Oncology, a ... and data analytics, formally announced today that George Clinical ... the transaction has the dual purpose of strengthening ... led oncology trial delivery solutions throughout the ...
Breaking Medicine Technology: